REG - Cambridge Cognition - £1 million contract for pivotal autoimmune trial

Cambridge Cognition HoldingsAnnouncement

28/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220328:nRSb1491Ga&default-theme=true

RNS Number : 1491G  Cambridge Cognition Holdings PLC  28 March 2022

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins £1 million contract as the

cognitive assessment partner for pivotal autoimmune trial

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
won a contract worth just over £1 million with a top 10 pharmaceutical
company to provide digital cognitive assessments for a pivotal phase III
autoimmune disease trial. Revenue from the contract is expected over the next
three years.

 

Autoimmune diseases occur when a person's immune system mistakenly attacks
healthy cells(1) which, for some patients, can result in cognitive impairment.
With the prevalence of autoimmune disease on the rise(2), there is an urgency
to develop better treatments. This need has resulted in a 40% increase in
clinical trials for autoimmune conditions in the last decade(3). Nevertheless,
treatment options for the associated cognitive impairment are limited.

 

This top 10 pharmaceutical company has selected Cambridge Cognition as the
cognitive assessment provider for its pivotal trial as they believe the
Company has the technology and infrastructure to deliver rapid, sensitive
cognitive assessments at scale. The trial aims to recruit and test hundreds of
participants across nearly 40 countries.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Phase III clinical trials are the large, final stage in drug development as
pharmaceutical companies can use the results to seek regulatory approval.
 Cambridge Cognition is well positioned to deliver these pivotal, global
trials with its gold standard solutions. Strategically, this contract sees the
Company operate in a high growth space with a leading pharmaceutical company
that is committed to tackling diseases in this therapeutic area."

 

References

1.
https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
(https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm)

2.        Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin
DC, Chan EKL, Miller FW. Increasing Prevalence of Antinuclear Antibodies in
the United States. Arthritis Rheumatol. 2020 Jun;72(6):1026-1035. doi:
10.1002/art.41214. Epub 2020 Apr 30. PMID: 32266792; PMCID: PMC7255943.

3.        Informa Trial Trove Search: Autoimmune Trials Search 2010 -
2020

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                         Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)

 Sally Jennings, Head of Marketing & Communications
 Panmure Gordon (UK) Limited (NOMAD and Broker)

 Freddy Crossley, Emma Earl (Corporate Finance)           Tel: 020 7886 2968

 Rupert Dearden (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                   Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTZZGZFZNFGZZM